ArticleBreast cancer research : BCR2025
Cardiovascular disease risk following radiotherapy among breast cancer survivors: a nationwide cohort study in South Korea.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundWhile radiotherapy (RT) improves breast cancer survival outcomes, concerns persist regarding radiation-induced cardiovascular complications. We aimed to evaluate the incidence and risk of radiation-associated cardiovascular disease (CVD) among breast cancer survivors.
methodsThis population-based retrospective cohort study included 38,045 female breast cancer survivors in South Korea who survived at least 1 year following diagnosis between 2012 and 2019. Cumulative incidence of CVD was estimated using the cumulative incidence function accounting for competing risks. Hazard ratios (HRs) for radiation-associated CVD were calculated using cause-specific Cox proportional hazards models with adjustments for potential confounders.
resultsAmong the study population, 67.8% received RT. The RT group was younger at diagnosis, had fewer distant-stage cancers, and lower prevalence of pre-existing cardiovascular conditions compared to the non-RT group. The 9-year cumulative incidence of overall CVD was 32.8%, with higher rates in the non-RT group. RT was not significantly associated with increased risk of overall heart disease (HR: 0.94; 95% CI 0.88-1.01) or specific subtypes. No significant differences were observed between RT techniques. While no significant interaction was observed between RT and chemotherapy for overall heart disease risk (p = 0.2641), a significant interaction was identified for heart failure (p = 0.0013); patients receiving both RT and chemotherapy exhibited an increased risk (HR: 1.31; 95% CI 1.03-1.65) compared to those receiving neither treatment.
conclusionsRT was not significantly associated with increased overall CVD risk, nor were there significant differences based on RT technique or its combination with chemotherapy for most cardiac outcomes. However, combined RT and chemotherapy significantly elevated heart failure risk, suggesting a potential interaction effect. Given the relatively short follow-up period, cautious interpretation of these results is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.